QFA
RPRX icon

Quattro Financial Advisors’s Royalty Pharma RPRX Stock Holding History

Quattro Financial Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,000
Closed -$902K – 96
2024
Q4 		$902K Hold
30,000
– – 0.23% 57
2024
Q3 		$833K Buy
+30,000
New +$831K 0.24% 49

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Quattro Financial Advisors's RPRX Position: Q1 2025 in Review

Quattro Financial Advisors sold out of Royalty Pharma (RPRX) in Q1 2025, closing a stake of 30,000 shares — an estimated $902K sold.

Quattro Financial Advisors first reported a position in RPRX in Q3 2024 and held it in 2 quarters. The position peaked at $902K in Q4 2024. 447 funds tracked by Wall St. Rank hold RPRX as of Q1 2025.

  • Quattro Financial Advisors reported no remaining Royalty Pharma position as of Q1 2025 after selling out during the quarter.
  • Quattro Financial Advisors sold 30,000 Royalty Pharma shares in Q1 2025, an estimated $902K.
  • Quattro Financial Advisors first reported a position in Royalty Pharma in Q3 2024 and held it in 2 quarters.
  • Quattro Financial Advisors's Royalty Pharma position peaked at $902K in Q4 2024.
  • 447 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2025.

Based on Quattro Financial Advisors's 13F filing for Q1 2025, filed 29 Apr 2025.